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Respiratory syncytial virus (RSV) can be recovered from plasmids that separately encode antigenomic RNA and the N, P,
L, and M2-1 proteins of the nucleocapsid. However, in a recent study the inclusion of a separate M2-1 expression plasmid
was found to be unnecessary (H. Jin, D. Clarke, H. Zhou, X. Cheng, K. Coelingh, M. Bryant, and S. Li, Virology 1998, 251,
206–214). This suggested that the M2-1 protein, which is a transcription antitermination factor, is not required to reconstitute
the minimum unit of infectivity, namely a nucleocapsid fully functional for viral transcription and RNA replication. Here we
show that the antigenomic plasmid is remarkably efficient as a substitute for an M2-1 expression plasmid in supporting
processive transcription by an RSV minigenome. Thus, the simple expedient of omitting an expression plasmid is invalid for
evaluating recovery requirements. The issue of the requirement of M2-1 for the recovery of infectious RSV is discussed.
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(Human respiratory syncytial virus (RSV) is the most
mportant agent of pediatric respiratory tract disease
orldwide (7). RSV is a pneumovirus of the paramyxovi-
us family and has as genome a single strand of nega-
ive-sense RNA that is 15,222 or 15,223 nucleotides in
ength for strain A2, depending on the particular biolog-
cal or recombinant isolate. The genome is transcribed
nto 10 mRNAs that in turn encode 11 proteins: the major
ucleocapsid protein N, the nucleocapsid phosphopro-
ein P, the polymerase L protein, the internal matrix pro-
ein M, the attachment glycoprotein G, the fusion glyco-
rotein F, the small hydrophobic protein SH, the non-
tructural proteins NS1 and NS2, and the M2-1 and M2-2
roteins which are encoded by two overlapping open
eading frames (ORFs) in the M2 mRNA (6, 7, 9). The RSV
ene order is 39-NS1-NS2-N-P-M-SH-G-F-(M2-1/M2-2)-L.
he M2-1 protein has been shown to be a transcription
ntitermination factor that promotes elongation during
RNA synthesis and read-through at gene junctions (5,
1a, 13, 14). On the other hand, RNA replication by model
inireplicons is independent of, and unaffected by, the
2-1 protein (5, 11a).
Infectious recombinant RSV was first shown to be
ecoverable from cDNA by the intracellular coexpression
f antigenomic RNA and the N, P, L, and M2-1 proteins,
ach encoded by a separate transfected plasmid (4).
1(
To whom reprint requests should be addressed. Fax: (301) 496-
312. E-mail: pcollins@atlas.niaid.nih.gov.
251lasmid expression is under the control of T7 RNA poly-
erase, which can be supplied either by a vaccinia virus
ecombinant or by a stably expressing cell line (2, 4). Two
ndependent studies indicated that it was necessary to
nclude the M2-1 expression plasmid (2, 4). However, in
subsequent study the M2-1 plasmid had no effect on
ecovery and indeed could be omitted entirely (16).
hese authors noted that it was formally possible that
he M2-1 protein was somehow supplied by the antige-
omic plasmid acting as support. If so, whether the M2-1
upport protein came from the M2-1 ORF contained
ithin the antigenomic plasmid or from a separate plas-
id, or for that matter from a stably expressing cell or a
accinia virus recombinant or some other form, would be
trivial operational difference and would in no way alter
he previous conclusion that M2-1 is required for recov-
ry (4). The fundamental issue is whether, for RSV, the
roteins required for the formation of the minimum unit of
nfectivity, namely a genomic nucleocapsid fully func-
ional for RNA replication and transcription, are N, P, and
alone, as has been reported for other nonsegmented
egative-strand RNA viruses, or whether the novel M2-1
ranscription antitermination factor is required in addi-
ion.
First, we reexamined whether recovery of RSV in our
ands was dependent on added M2-1 plasmid. This was
one using plasmid D53, which encodes an antigenomic
NA containing four introduced restriction site markers
4) and the “4C” mutation, which we described previously
8). This involves a G to C change (negative sense) at
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252 RAPID COMMUNICATIONosition 4 in the leader region and was shown previously
o greatly enhance recovery of a 7502-nucleotide nega-
ive-sense minigenome (8) as well as recovery of RSV
rom antigenomic cDNA (4, 16; and our unpublished
ata). Because of this latter property, this mutation has
een included in most of the recombinant RSV vaccine
andidates constructed to date (17, 18, 23, 24). Recovery
as performed as described previously (4), whereby
ells were simultaneously infected with the modified
accinia virus Ankara strain expressing T7 RNA polymer-
se (MVA-T7) (25) and transfected with five plasmids that
eparately encode antigenomic RNA and the N, P, L, and
2-1 proteins. This routinely resulted in levels of recov-
ry on the order of 10 to 150 plaques per well of 1.5 3 106
ells, consistent with our previous findings (4). When the
2-1 plasmid was omitted, most wells did not yield virus,
ut an occasional well yielded a reduced number of
laques (,10), which had not been observed in our
revious study (4). Thus, supplying a separate M2-1
xpression plasmid was not an absolute requirement.
owever, the increase in efficiency observed here in the
resence of added M2-1 expression plasmid indicates
hat the M2-1 protein strongly affects recovery. The an-
igenomic plasmid remained a potential source of M2-1
rotein. If indeed the antigenomic plasmid is a source of
2-1 protein, the inconsistent recovery of virus in the
bsence of added M2-1 plasmid in our experiments, and
he lack of effect of added M2-1 plasmid in the study of
in et al. (16), might simply be due to variability in the level
f expression.
We then tested whether M2-1 could be expressed from
he antigenomic plasmid in quantities sufficient to sup-
ort processive transcription. As an assay for M2-1 ac-
ivity, we modified a reconstituted transcription–replica-
ion system based on a cDNA-encoded negative-sense
inigenome, C2-L, which contains the luciferase gene
s a marker under the control of RSV transcription and
eplication signals and is complemented by N, P, L, and
2-1 support plasmids (7). Previous work showed that,
hen supported by the N, P, and L proteins alone and
nalyzed by Northern blot hybridization with a negative-
ense probe, C2-L directed the synthesis of mini-anti-
enome and a smear of incomplete mRNA of approxi-
ately 500 nucleotides or less, whereas synthesis of the
omplete 1780-nucleotide luciferase mRNA could not be
etected (7). Inclusion of M2-1 plasmid resulted in the
fficient synthesis of full-length luciferase mRNA, as de-
ermined both by Northern blot analysis and by lucif-
rase enzyme assay (7). We also previously showed that
his effect is specific to M2-1 and is not observed by
oexpression of any of the other RSV cDNAs and that
his effect requires an uninterrupted M2-1 ORF and thus
s mediated by its encoded protein (7). The activity of
2-1 in directing processive transcription also is illus-
rated in Table 1. When C2-L was supported by the N andplasmids alone (sample 1) there was a negligible tmount of luciferase activity. The additional inclusion of
he L plasmid (sample 2), which is sufficient to fully
econstitute RNA replication (12, 26), provided only a
-fold increase in luciferase expression. This might re-
lect a trace amount of synthesis of complete mRNA, but
lso might instead reflect translation of positive-sense
eplication products stabilized by vaccinia virus-medi-
ted capping and polyadenylation (12). The further inclu-
ion of the M2-1 plasmid in addition to L (samples 3–6)
esulted in a dose-dependent increase in the expression
f luciferase of up to 270-fold over the N, P, and L sample,
eflecting the antitermination activity of M2-1. The addi-
ion of input M2-1 plasmid in amounts greater than 100
g per well did not provide a further increase in lucif-
rase expression (7, 11a).
We then tested whether the support activity of the
2-1 plasmid could be replaced by antigenomic plasmid
53 (Table 1, samples 7–9) or D56 (samples 10–12), the
atter being a derivative of D53 that is identical except
hat it lacks the 4C mutation. We also tested in parallel
TABLE 1
Expression of Luciferase Enzyme from Minigenome C2-L Comple-
ented by the N, P, and L Plasmids and Various Plasmids Containing
he M2-1 ORFa
Sample
Plasmids
C2-L, N, P, L1 Luciferase activityb
1 L omitted 6.1
2 No addition 23.5
3 1.6 ng M2-1 543.6
4 8 ng M2-1 2025.0
5 40 ng M2-1 5172.0
6 100 ng M2-1 6335.0
7 100 ng D53 35.6
8 400 ng D53 70.9
9 1000 ng D53 209.3
10 100 ng D56 47.4
11 400 ng D56 114.8
12 1000 ng D56 508.4
13 100 ng G-F-M2 74.1
14 400 ng G-F-M2 229.6
15 1000 ng G-F-M2 612.4
16 100 ng F-M2 218.2
17 400 ng F-M2 445.9
18 1000 ng F-M2 1126.0
a HEp-2 cells (1.5 3 106 cells per well) were simultaneously infected
tih 10 PFU per cell of vTF7-3 and transfected with 0.2, 0.4, 0.3, and 0.1
g, respectively, of plasmid C2-L, N, P, and L, plus the indicated
dditional plasmid (7). Cells were incubated at 32°C, harvested at 72 h,
nd assayed for luciferase activity (19). The nucleotide lengths of the
dditional plasmids are M2-1, 5914; D53 or D56, 19,168; G-F-M2, 6403;
nd F-M2, 6205. Hence, between plasmids, relative amounts by mass
re approximately equal to relative molar amounts except in the case
f the large D53 or D56 plasmids, which each would be 3.24-fold lower
n a molar basis than an equivalent mass of M2-1 plasmid. Hence,
000 ng of D53/56 plasmid corresponds to 309 ng of M2-1 plasmid.
b Luciferase light units per 6000 cells.wo subclones of the antigenome plasmid, namely plas-
m
g
c
F
c
t
m
p
u
p
o
w
r
c
u
m
m
s
s
f
v
t
M
r
s
d
p
c
s
N
w
t
n
i
2
v
a
P
h
c
c
r
t
n
h
s
c
M
t
p
m
w
s
p
a
M
t
t
o
h
f
a
p
f
e
M
d
a
s
e
w
g
i
t
w
e
a
i
v
t
I
3
a
p
c
b
t
m
P
N
N
N
N
N
N
P
N
N
i
a
253RAPID COMMUNICATIONid G-F-M2 (samples 13–15), which contains anti-
enome nucleotides 4620–8506 (PacI–BamHI) and in-
ludes solely the three indicated genes, and plasmid
-M2 (samples 16–18), which contains antigenome nu-
leotides 5610–8506 (StuI–BamHI) and includes solely
he two indicated genes. Neither of the latter two plas-
ids contains a T7 promoter, which tests whether the T7
romoter is necessary for expression from a plasmid
nder these conditions. Inclusion of an antigenomic
lasmid increased luciferase expression up to 22-fold
ver the N, P, and L sample, whereas the fold increase
ith the G-F-M2 and F-M2 plasmids was 26 and 48,
espectively. Thus, inclusion of a variety of plasmids
ontaining the M2-1 ORF provided M2-1 activity that was
p to 18% of the maximum obtained with an M2-1 plas-
id in which the cDNA is under the control of the pro-
oter for T7 RNA polymerase and the translational start
ite of the ORF is linked to the internal ribosome entry
ite of encephalomyocarditis virus and thus is designed
or high-efficiency expression (11).
In a second experiment (Table 2), we compared the
TF7-3 vaccinia virus recombinant, which was used in
he above-mentioned minigenome experiment, with the
VA-T7 recombinant that was used in the earlier virus
ecovery experiments. The two recombinants yielded es-
entially similar results. These results also provided ad-
itional confirmation that antigenomic plasmid can com-
lement minigenome transcription with remarkable effi-
iency. In this experiment, the addition of M2-1 plasmid
timulated luciferase expression up to 538-fold over the
, P, and L sample. When the M2-1 expression plasmid
as replaced with an antigenomic plasmid, the stimula-
ion was up to 35.5-fold.
In this experiment, we also tested whether the antige-
TABLE 2
Expression of Luciferase Enzyme from Minigenome C2-L Comple-
ented by the N, P, and L Plasmids and M2-1 Plasmid or Antigenomic
lasmida
Plasmid C2-L1 Sample
Luciferase
activitya
(MVA-T7) Sample
Luciferase
activityb
(vTF7-3)
, P 1 2.7 10 3.5
, P, L 2 22.0 11 67.7
, P, L, 100 ng M2-1 3 11,840.0 12 14,610.0
, P, L, 250 ng D53 4 758.8 13 617.3
, P, L, 500 ng D53 5 750.9 14 495.6
, P, L, 1000 ng D56 6 779.9 15 647.0
, L, 1000 ng D56 7 5.3 16 3.6
, L, 1000 ng D56 8 4.5 17 3.3
, P, 1000 ng D56 9 6.8 18 8.5
a Transfections were performed as described in Table 1, with the
ndicated vaccina virus recombinant added at 10 PFU per cell. Input
mounts of the C2-L, N, P, and L plasmids were as in Table 1.
b Luciferase light units per 15,000 cells.omic plasmid could substitute for the N, P, or L plasmid an the presence of the M2-1 plasmid. As shown in Table
, replacement of any one of these plasmids resulted in
ery low levels of luciferase activity. The inability of the
ntigenomic plasmid to substitute efficiently for the N or
plasmid might be due to the requirement for relatively
igh, balanced levels of each protein (12), and in the
ase of L the large size of the gene might be a compli-
ation. In contrast, the M2-1 ORF is relatively short, and
elatively little M2-1 is required to confer processive
ranscription. For example, as shown in Table 1, even 1.6
g per well of M2-1 plasmid was sufficient to confer very
igh levels of luciferase expression. Another study
howed that sequential transcription on minigenomes
ontaining as many as five genes was dependent on
2-1, but required very small amounts of M2-1 plasmid
o confer processivity (11a). Furthermore, since the com-
lete RSV genome encodes an M2 mRNA, whereas the
inigenomes do not, it is likely that much less M2-1
ould be required in trans to establish processive tran-
cription of the genome. Specifically, if a small amount of
rocessive RSV transcription can be coaxed by a trace
mount of M2-1, the resulting synthesis and translation of
2 mRNA would trigger a positively regulated amplifica-
ion of sequential transcription.
One likely mechanism for the expression of M2-1 from
he antigenomic plasmid or its derivatives is promiscu-
us transcription by vaccinia virus RNA polymerase. This
as been observed before: for example, it is a common
inding that plasmid-borne marker genes such as chlor-
mphenicol acetyl transferase or luciferase can be ex-
ressed with remarkably high efficiency when trans-
ected into vaccinia virus-infected cells (12, and refer-
nces therein). This likely accounts for the majority of
2-1 expressed from the G-F-M2 and the F-M2 plasmids
escribed here, each of which lacks a T7 promoter. This
lso could be the basis for expression of M2-1 in the
tudy of Jin et al. (16) since the MVA-T7 recombinant was
mployed. Incidently, this effect was not observed here
ith regard to luciferase expression by the C2-L mini-
enome because the design of the minigenome plasmid
ncluded the deliberate introduction of several copies of
he termination signal for vaccinia virus early genes,
hich greatly reduced the high levels of promiscuous
xpression that we initially observed (7, 12). Other mech-
nisms for expression of plasmid-borne ORFs that are
ndependent of vaccinia virus transcription exist. The
ery large amount of antigenomic RNA synthesized in-
racellularly by T7 RNA polymerase can act as an mRNA.
n a recovery system for human parainfluenza virus type
comparable to that described here for RSV, Hoffman
nd Banerjee (15) showed that inclusion of the N support
lasmid was unnecessary for virus recovery. There, the
onclusion was not that the N protein was unnecessary,
ut rather that it was efficiently expressed from the an-
igenomic RNA, in which it is the 59-proximal ORF. As
nother example of translational initiation at a site far
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254 RAPID COMMUNICATIONrom the 59 end of an RNA, the X protein of Sendai virus
s expressed efficiently by translational initiation at the
ixth AUG in the P mRNA, presumably through internal
ibosome entry or leaky scanning (10). Furthermore, frag-
entation of an RNA can render an internal ORF trans-
atable. This was demonstrated with Sindbis virus
enomic RNA, which is a large mRNA whose down-
tream end contains an ORF for the structural proteins
hat normally is translationally silent in the complete
enomic RNA and is translated only from a subgenomic
NA. However, these structural proteins can be ex-
ressed from genomic RNA fragments (1). Furthermore,
n ORF contained in a plasmid transfected into unin-
ected cells can be expressed independent of the pres-
nce of any known promoter or added polymerase. For
xample, transfection of cells with pBR322 containing a
omplete cDNA of poliovirus resulted in the recovery of
irus (20) despite the large size of the poliovirus genome,
ts requirement for correct RNA ends, and the apparent
ack of eukaryotic promoters. Thus, in any experimental
ituation in which DNA containing the M2-1 ORF is in-
roduced into cells, one cannot exclude the possibility
hat expression occurs. Conditions that avoid the use of
accinia virus, or use a plasmid that supplies genomic
ather than antigenomic RNA, would not necessarily be
ufficient to rule out a low level of expression from DNA.
n addition, as mentioned above, it is likely that very little
2-1 protein would be required to achieve recovery,
articularly because even a trace amount supplied in
rans would be anticipated to trigger a positively regu-
ated amplification mediated by the RSV polymerase.
If one hypothesizes that the M2-1 protein is not re-
uired to make a functional nucleocapsid capable of
aunching a productive infection, and therefore is a non-
ssential transcription factor, it should be possible to
elete its ORF from recombinant virus, to block its ex-
ression such as by introducing translational stop
odons, or to inactivate the antitermination activity of its
ncoded protein by amino acid substitutions. RSV has
roven to be remarkably plastic in its ability to sustain
ene knock-outs without losing the capacity to grow in
ell culture, and indeed 5 of the 11 RSV ORFs have been
eleted or inactivated to date (2, 3, 22; M. Teng, A.
ermingham, and P. L. Collins, unpublished data). This
lso would represent the only experimental situation in
hich a functional M2-1 ORF would not be present,
nsuring that trans-complementation does not occur. It is
ormally possible that M2-1 has an additional function,
esides that of being a transcription factor, that is es-
ential and therefore might preclude its deletion. How-
ver, studies with model minigenomes seemed to rule
ut a role for M2-1 in RNA replication (7, 11a) or in
ackaging and passage (21). Therefore, the production of
irus in which expression of the M2-1 ORF has been
blated, or the antitermination activity of its protein spe-
ifically ablated, is the critical test necessary to showhat this protein is not required for recovery. In the mean-
ime, all available evidence supports the previous view
4, 7) that the M2-1 protein is an essential component of
fully functional RSV nucleocapsid and that it must
e supplied by some means in order to obtain virus
ecovery.
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